These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34519101)

  • 21. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.
    Peiseler M; Schwabe R; Hampe J; Kubes P; Heikenwälder M; Tacke F
    J Hepatol; 2022 Oct; 77(4):1136-1160. PubMed ID: 35750137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic Fatty Liver Disease Demonstrates a Pre-fibrotic and Premalignant Molecular Signature.
    Almanza D; Gharaee-Kermani M; Zhilin-Roth A; Rodriguez-Nieves JA; Colaneri C; Riley T; Macoska JA
    Dig Dis Sci; 2019 May; 64(5):1257-1269. PubMed ID: 30519850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells.
    Shen H; Yu H; Li QY; Wei YT; Fu J; Dong H; Cao D; Guo LN; Chen L; Yang Y; Xu Y; Wu MC; Wang HY; Chen Y
    Acta Pharmacol Sin; 2022 Nov; 43(11):2917-2928. PubMed ID: 35508720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1.
    Gallage S; Ali A; Barragan Avila JE; Seymen N; Ramadori P; Joerke V; Zizmare L; Aicher D; Gopalsamy IK; Fong W; Kosla J; Focaccia E; Li X; Yousuf S; Sijmonsma T; Rahbari M; Kommoss KS; Billeter A; Prokosch S; Rothermel U; Mueller F; Hetzer J; Heide D; Schinkel B; Machauer T; Pichler B; Malek NP; Longerich T; Roth S; Rose AJ; Schwenck J; Trautwein C; Karimi MM; Heikenwalder M
    Cell Metab; 2024 Jun; 36(6):1371-1393.e7. PubMed ID: 38718791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Wnt/beta-catenin signaling and its modulators in nonalcoholic fatty liver diseases.
    Shree Harini K; Ezhilarasan D
    Hepatobiliary Pancreat Dis Int; 2023 Aug; 22(4):333-345. PubMed ID: 36448560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function.
    Wolff G; Sakurai M; Mhamane A; Troullinaki M; Maida A; Deligiannis IK; Yin K; Weber P; Morgenstern J; Wieder A; Kwon Y; Sekar R; Zeigerer A; Roden M; Blüher M; Volk N; Poth T; Hackert T; Wiedmann L; De Angelis Rigotti F; Rodriguez-Vita J; Fischer A; Mukthavaram R; Limphong P; Tachikawa K; Karmali P; Payne J; Chivukula P; Ekim-Üstünel B; Martinez-Jimenez CP; Szendrödi J; Nawroth P; Herzig S
    Mol Metab; 2022 Jun; 60():101487. PubMed ID: 35378329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice.
    Yang A; Yan X; Fan X; Shi Y; Huang T; Li W; Chen W; Jia J; You H
    Hepatol Int; 2021 Oct; 15(5):1122-1135. PubMed ID: 34014450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
    Widjaja AA; Singh BK; Adami E; Viswanathan S; Dong J; D'Agostino GA; Ng B; Lim WW; Tan J; Paleja BS; Tripathi M; Lim SY; Shekeran SG; Chothani SP; Rabes A; Sombetzki M; Bruinstroop E; Min LP; Sinha RA; Albani S; Yen PM; Schafer S; Cook SA
    Gastroenterology; 2019 Sep; 157(3):777-792.e14. PubMed ID: 31078624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
    Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
    J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HuR mediates motility of human bone marrow-derived mesenchymal stem cells triggered by sphingosine 1-phosphate in liver fibrosis.
    Chang N; Ge J; Xiu L; Zhao Z; Duan X; Tian L; Xie J; Yang L; Li L
    J Mol Med (Berl); 2017 Jan; 95(1):69-82. PubMed ID: 27543493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic Lipidomics and Molecular Imaging in a Murine Non-Alcoholic Fatty Liver Disease Model: Insights into Molecular Mechanisms.
    Rodríguez-Calvo R; Samino S; Girona J; Martínez-Micaelo N; Ràfols P; García-Altares M; Guaita-Esteruelas S; Junza A; Heras M; Yanes O; Correig X; Masana L
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32899418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term profile of serological biomarkers, hepatic inflammation, and fibrosis in a mouse model of non-alcoholic fatty liver disease.
    Toita R; Kang JH
    Toxicol Lett; 2020 Oct; 332():1-6. PubMed ID: 32579995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of CDK4 Triggers Development of Non-alcoholic Fatty Liver Disease.
    Jin J; Valanejad L; Nguyen TP; Lewis K; Wright M; Cast A; Stock L; Timchenko L; Timchenko NA
    Cell Rep; 2016 Jul; 16(3):744-56. PubMed ID: 27373160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
    Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HuR/methyl-HuR and AUF1 regulate the MAT expressed during liver proliferation, differentiation, and carcinogenesis.
    Vázquez-Chantada M; Fernández-Ramos D; Embade N; Martínez-Lopez N; Varela-Rey M; Woodhoo A; Luka Z; Wagner C; Anglim PP; Finnell RH; Caballería J; Laird-Offringa IA; Gorospe M; Lu SC; Mato JM; Martínez-Chantar ML
    Gastroenterology; 2010 May; 138(5):1943-53. PubMed ID: 20102719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development.
    Sobolewski C; Abegg D; Berthou F; Dolicka D; Calo N; Sempoux C; Fournier M; Maeder C; Ay AS; Clavien PA; Humar B; Dufour JF; Adibekian A; Foti M
    Gut; 2020 Oct; 69(10):1841-1854. PubMed ID: 31919231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholic acid supplementation accelerates the progression of nonalcoholic fatty liver disease to the procarcinogenic state in mice fed a high-fat and high-cholesterol diet.
    Chun HJ; Shim YJ; Kwon YH
    J Nutr Biochem; 2022 Feb; 100():108869. PubMed ID: 34563665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A non-mitogenic FGF4 analog alleviates non-alcoholic steatohepatitis through an AMPK-dependent pathway.
    Wang L; Dong W; Gao H; Chen C; Liang S; Ye X; Liu Y; Hou Y; Fan L; Pan T; Wang Z; Chen Y; Luo Y; Song L
    Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166560. PubMed ID: 36167161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model.
    Heo YJ; Choi SE; Lee N; Jeon JY; Han SJ; Kim DJ; Kang Y; Lee KW; Kim HJ
    J Gastroenterol Hepatol; 2021 Sep; 36(9):2592-2600. PubMed ID: 33600604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.